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Abstract
Background: Chronic headache (CrH) occurs commonly in the population, and chronic migraine (CM) accounts for
much of the CrH. Diagnostic criteria for CM remain controversial, and this could lead to undertreatment of CM. The
purpose of this study was to analyze the clinical profiles of CM and to field test the International Classification of
Headache Disorders-3β criteria (ICHD-3β) and Expert Opinion criteria (EO) for CM application.
Methods: We retrospectively reviewed the medical records of CrH patients in our headache clinic during the
period. Eligible patients were selected from CrH population based on Silberstein and Lipton criteria (S-L) for CM,
and meanwhile fulfilled with migraine days at least 8 days/month. Then we evaluated the characteristics of clinic
profiles and outcomes between patients diagnosed CM using ICHD-3β and EO criteria. Field tested the CM criteria
Of ICHD-3β and EO.
Results: In a total of 710 CrH patients , 261 (36.8 %) were recruited with CM based on both S-L criteria and fulfilled
at least 8 migraine days/month. Be understandable, all the 261 patients met the EO criteria, and only 185 (70.9 %)
met ICHD-3β for CM. For the 76 patients who met EO but not ICHD-3β, 70 had atypical migraine attacks (probable
migraine, PM), and another 6 had typical migraine attacks but less than a total history of 5 attacks. Although 173
(66.3 %) were concurrent with medication overuse, just one patient overused triptans and none used ergot agents.
Clinical features were not significantly different between the ICHD-3β and EO criteria groups (P > 0.05), and neither
were outcomes of prophylaxis (P = 0.966). Total migraine prophylaxis effectiveness was 73 %.
Conclusion: Migraine-specific analgesics are rarely used in China, permitting patients with PM to avail themselves
of “migraine days” is a reasonable accommodation for this difficult condition. In our hands, use of the new EO
criteria for diagnosis of CM increases the sensitivity and maintains the specificity of decision making, and therefore
should be adopted in CM management practice.
Keywords: Chronic disease, Humans, International classification of diseases, Migraine disorders/classifications,
Migraine disorders/diagnosis
Background
Chronic headache (CrH) refers to a group of headache
disorders occurring at least 15 days/month exceeding
3 months, including those associated with medication
overuse [1, 2]. Approximately 3 to 5 % of the adult
population worldwide have CrH [2]. In practice, the
most common form of CrH in patients presenting to
headache clinics is CM [2–6]. However, the diagnostic
criteria for CM remain controversial.
Transformed migraine (now called chronic migraine,
CM) was first proposed by Silberstein and Lipton (S-L)
in 1994 [6]. It was classified as CM with or without
medication overuse (CM+ and CM-, respectively) [6].
CM criteria were standardized in the Second Edition of
the International Classification of Headache Disorders
(ICHD-2) in 2004, which required migraine symptoms
to be present at least 15 days/month and excluded medi-
cation overuse headache (MOH) [7]. Revised criteria
(ICHD-2R) published in 2006 modified this, requiring
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headache at least 15 days/month but also migraine
symptoms on at least 8 days. It was still difficult to apply
these ICHD-2R criteria in patients with MOH [8].
The International Classification of Headache Disor-
ders, 3rd edition, beta version (ICHD-3β) was published
in 2013 [9]. The ICHD-3β criteria for CM require head-
ache at least 15 days/month for least 3 months; it in-
cludes migraine with or without aura and believed
migraine day relieved by a triptan or ergot derivative, on
at least 8 days/month. It also allows CM with and with-
out MOH [9]. However, CrH with probable migraine
(PM) are not considered while diagnoses CM by ICHD-
3β criteria, not mention the situation that migraine-
specific analgesics are still not available worldwide.
Thankfully, a paper describing Expert Opinion on diag-
nostic criteria for CM was published in 2014 [10]. The
criteria address PM for treatment of headache with trip-
tans and ergot derivatives [10]. Thus, the purpose of this
study was to perform field testing of the ICHD-3β and




A retrospective study was conducted in the headache
clinic of the First Affiliated Hospital of Chongqing
Medical University in China. Consecutive patient visits
presenting with a principal complaint of headache from
January 2013 to December 2015 were candidate for this
study.
All headache patients with CrH were reviewed by two
doctors independently (H.J., Y.D). The diagnosis of CrH
was confirmed with at least 15 days/month over a period
lasting more than 3 months, which had been defined in
our previous study [11]. Eligible patients were selected
from CrH if their signs and symptoms fulfilled the cri-
teria for CM according to S-L criteria [6], and with mi-
graine days at least 8 days/month [12]. Patients with
other primary CrH (chronic tension-type headache
(CTTH), new daily persistent headache (NDPH) and
chronic cluster headache et al.) and secondary headaches
were excluded [13]. MRI and/or CT scans were per-
formed if clinically necessary. If the headache could not
be accurately categorized as either primary or secondary,
it was classified as headache not otherwise specified
(headache NOS) [11].
The patients were treated empirically with flunarizine
(5 mg/day), amitriptyline (25–50 mg/day), topiramate
(75 mg/day), metoprolol (25–50 mg/day) or venlafaxine
(75 mg/day), based on the specialist’s judgements (JY
Zhou) and patient’s preferences. Additionally, overused
analgesics were withdrawn in order to address MOH.
Patients were informed to discontinue the overused an-
algesics and meanwhile started prophylactic treatment.
Medication responses were classified as significant ef-
fectiveness (50 % reduction in headache days of moder-
ate to severe headache), partial effectiveness, and no
improvement or worsening symptoms.
Date collection
All individuals presenting with a principal complaint of
headache were interviewed face-to-face by a headache
specialist (JY Zhou). The medical history and a detailed
structured self-administered questionnaire were com-
pleted by 7 doctors (H.J., Y.D,, Y. Z., J.J., X.K., Q.Z.,
K.W). The questionnaire was validated for headache
diagnosis by previous study [5, 11, 14], and included the
following components: demographic characteristics, clin-
ical features of headache (onset age, course, location,
duration, frequency, intensity, aggravation after physical
activity and associated symptoms); history of head in-
jury; past medical history and drug intake for headache;
family history. Treatment follow up was then at a 3 to 6-
month visit for face-to-face consult, or by telephone in-
terviews, based on previous trials that the migraine pre-
vention should reasonably last for 3–6 months for
response and tolerability evaluation [15, 16].
Standard study protocol and patient consents
Our study protocol was approved by the hospital ethics
board. All patients gave their informed consent before
collecting headache information.
Statistical analysis
Statistical analysis was performed using SPSS software,
version 20.0 (Chicago, IL, USA). The characteristics of
the study population were analyzed using descriptive sta-
tistics. Quantitative variables were expressed as mean ±
standard deviation (SD). Qualitative variables were
expressed as frequency (proportion). The Student’s t test
and chi-squared test were used for comparison of clin-
ical parameters between groups. P < 0.05 was considered
to be statistically significant.
Results
During the study period (January 2013 to December
2015), 2733 patient visits with main complaint of head-
ache were recorded (Fig. 1). A total of 710 (26.0 %) had
CrH. Of the CrH patients, 261 (36.8 %) patients were di-
agnosed as CM based on the S-L criteria, 14.1 % (100/
710) had CTTH, 2 % (14/710) had NDPH, 8.3 % (59/
710) other primary headache, 28.2 % (200/710) second-
ary headache and 10.7 % (76/710) headache NOS. CM
patients were female predominant (73.2 %) and the
mean age was 49.5 years (range from 11 to 83 years).
Jiang et al. The Journal of Headache and Pain  (2016) 17:85 Page 2 of 7
The classification of CM using ICHD-3β and EO criteria
Among 261 CM patients, 66.3 % (173/261) overused
medication. Of the 88 CM patients without medication
overuse, 100 % met EO criteria for CM, but only 62
(70 %) fulfilled ICHD-3β criteria for this diagnosis, as 26
patients had PM being not included in ICHD-3β. Pa-
tients with medication overuse were classified as MOH
according to ICHD-3β and EO criteria which allow both
CM and MOH diagnoses. Of the 173 CM patients with
documented medication overuse, 123 (71.1 %) patients
fulfilled CM and MOH based on ICHD-3β, other 50 pa-
tients were diagnosed with PM. In contrast, all 173
(100 %) patients fulfilled CM and MOH based on EO
(Table 1). In total, of 261 CM patients, 70.9 % (185)
fulfilled ICHD-3β criteria for CM, and all 261 patients
fulfilled EO criteria for CM.
Table 2 summarizes the subtypes of migraine in CM
based on ICHD-3β and EO. The subtypes of migraine
based on S-L criteria for CM include migraine without
aura (MO), migraine with aura (MA), and PM. Among
all 261 patients, there were 183 patients meeting the cri-
teria for MO, 8 patients with MA and 70 patients meet-
ing the criteria for PM. Of the 183 MO patients, 177
(96.7 %) patients fulfilled MO based on ICHD-3β criteria
for CM, other 6 patients just had less than 5 migraine
episodes. 8 (100 %) MA patients fulfilled MA subtypes.
The migraine subtypes in EO were in accordance with
those in S-L criteria.
Fig. 1 Flow chart of the study. CTTH: chronic tension-type headache; NDPH: new daily persistent headache; Headache NOS: headache not otherwise
specified; CM: chronic migraine ; CM- : chronic migraine without medication overuse; CM+: chronic migraine with medication overuse;
ICHD-3β: International Classification of Headache Disorders,3rd edition beta version; EO: Expert Opinion criteria; MOH: medication overuse headache
Table 1 Classification of patients with CM based on S-L, using
ICHD-3β and EO
S-L ICHD-3β n (%) EO n (%)
261 185 (70.9 %) 261 (100 %)
CM-, n = 88 CM 62 (70.5 %) CM 88 (100 %)
CM+, n = 173 CM +MOH 123 (71.1 %) CM +MOH 173 (100 %)
Abbreviations: S-L silberstein and lipton criteria, CM chronic migraine without
medication overuse, CM+ chronic migraine with medication overuse, ICHD-3β
international classification of headache disorders,3rd edition beta version, EO
expert opinion criteria, CM chronic migraine, CM +MOH chronic migraine with
medication overuse headache
Table 2 Subtypes of migraine in CM based on ICHD-3β and EO
S-L ICHD-3β n (%) EO n (%)
n = 261 185 (70.9 %) 261 (100 %)
MO, n = 183 MO 177 (96.7 %) MO 183 (100 %)
MA, n = 8 MA 8 (100 %) MA 8 (100 %)
PM, n = 70 – – PM 70 (100 %)
Abbreviations: S-L silberstein and lipton criteria, MO migraine without aura, MA
migraine with aura, PM probable migraine, ICHD-3β international classification
of headache disorders, 3rd edition beta version, EO expert opinion criteria
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The clinical features of CM by ICHD-3β and EO criteria
The clinical features of CM patients based on ICHD-3β
and EO criteria are shown in Table 3. Demographic pro-
files showed no significant differences. Mean age was
from 48.5 to 49.5 years, and females predominated
(73.2–74.1 %). The body mass index averaged from 22.9
to 23.2, within the normal range. The majority of pa-
tients (77.8–78.9 %) had not completed high school.
No headache characteristics were significantly different
between the ICHD-3β and EO groups. Frequency of head-
ache was almost identical (23.5–23.7 days per month) by
either standard. The courses of migraine were 16.8–
17.4 years and the courses of CM were 6.2–6.8 years. The
mean age of onset of migraine was 31.7–32.1 years and
the mean onset age of CM was 42.3–42.9 years. Most pa-
tients (82.5–82.7 %) took analgesic medications. About
half (48.8–52.6 %) used combination analgesics, and 41.6–
44.7 % of patients were taking multiple analgesics. Just
5.8–6.5 % of patients used simple analgesics. No patients
ever used ergots, and only one patient tried triptans.
About 54 % of patients had family headache history.
Treatment outcomes
A total of 250 patients received migraine prophylaxis (flu-
narizine, n = 141; amitriptyline, n = 58; topiramate, n = 20;
metoprolol, n = 25; and venlafaxine, n = 6). Of these, 62
patients (25 %) were lost to follow-up (flunarizine, n = 38;
amitriptyline, n = 14; topiramate, n = 4; and metoprolol,
n = 5). The causes of lost were of incorrect telephone
numbers (n = 54), or refusal to follow-up (n = 7). One
patient discontinued venlafaxine due to nausea.
Figure 2 summarizes the treatment response of CM.
There was no difference between groups in ICHD-3β
and EO (P = 0.966). A total of 71.6–72.9 % of the pa-
tients had significant reduction of headaches, 15.4–
16.4 % of patients had a partial response and the balance
(11–12 %) had no improvement which meant these pa-
tients had no response to migraine prophylaxis.
Discussion
This was the first study to evaluate clinical applicability
of ICHD-3β and EO criteria for CM. CM is a disabling
disorder that is underdiagnosed and undertreated [17].
The prevalence rate of CM is variable. A systematic re-
view in 2003 summarized 12 population-based studies
using several definitions for frequent migraine and deter-
mined that the global prevalence of CM varied from 0.0
to 5.1 %, with most estimates in the range of 1.4 to
2.2 % [18]. In our study, among 2733 headache patients,
a total of 710 patients had CrH. Of the CrH patients,
26.1 % (185/710) patients fulfilled ICHD-3β criteria for
CM, but 36.8 % (261/710) patients were diagnosed CM
based on EO, and the benefit outcomes who received
migraine prophylaxis were identical between the two
groups.
In a large US population-based sample, CM accounted
for 7.68 % of all migraine cases based on ICHD-2 [19].
Another study, at the Danish Headache Centre, showed
that CM accounted for 4.3 % of migraine or tension-type
headache based on ICHD-2R [13]. It appears that the
proportion of CM varied because of different population
sampling techniques or diagnostic criteria.
Table 3 Clinical features of CM based on ICHD-3β and EO
criteria
ICHD-3β EO P-value
n = 185 n = 261
Age (years), mean (SD) 48.5 ± 11.4 49.54 ± 11.5 0.364
Gender, n (%) 0.837
Female 137 (74.1 %) 191 (73.2 %)
Male 48 (24.9 %) 70 (26.8 %)
BMI, mean (SD) 23.2 ± 3.7 22.9 ± 3.6 0.418
Educational level, n (%) 0.783
< high school 149 (77.8 %) 206 (78.9 %)
≥ high school 42 (22.2 %) 55 (21.1 %)
Frequency of headache days,
mean (SD)
23.5 ± 6.4 23.7 ± 6.4 0.750
Frequency of migraine days,
mean (SD)
19.9 ± 7.9 20.4 ± 7.9 0.519
Age of onset of migraine,
mean (SD)
31.7 ± 12.1 32.1 ± 12.4 0.727
Courses of migraine,
mean (SD)
16.8 ± 10.9 17.4 ± 11.7 0.588
Age of onset of CM,
mean (SD)
42.3 ± 12.0 42.9 ± 12.1 0.624
Courses of CM, mean (SD) 6.2 ± 8.2 6.8 ± 8.4 0.503
Currently used acute analgesics, n (%) 0.811
Yes 154 (83.2 %) 215 (82.5 %)
No 31 (16.8 %) 46 (17.6 %)
Category of used analgesics, n (%) 0.773
Single analgesics 9 (5.8 %) 14 (6.5 %)
Combination analgesics 81 (52.6 %) 105 (48.8 %)
Multiple analgesics 64 (41.6 %) 96 (44.7 %)
Ergots 0 0
Triptans 1 (0.6 %) 1 (0.5 %) 0.813
Medication overuse, n (%) 0.964
Yes 123 (66.5 %) 173 (66.3 %)
No 62 (33.5 %) 88 (33.7 %)
Family headache history, n (%) 0.995
Yes 100 (54.1 %) 141 (54.0 %)
No 85 (45.9 %) 120 (46.0 %)
Abbreviations: CM chronic migraine, BMI body mass index, ICHD-3β
international classification of headache disorders,3rd edition beta version, EO
expert opinion criteria
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At present, there is no “gold standard” for diagnosis of
CM in clinical practice. ICHD-3β is still considered to
be a testing version, and the revised criteria (EO) were
proposed in 2014. Table 4 showed the diagnostic criteria
of CM.
The three systems of criteria recognize CM with
medication overuse. The S-L criteria have been used
widely in clinical practice. The criteria required a his-
tory of migraine or increasing headache frequency with
decreasing severity of migrainous features over at least
3 months, and required a history of transformation. In
current opinion, CM is not considered to be a compli-
cation of migraine, so the transformation process form
episodic attack to continuous pain is not essential con-
dition. Previous study showed that CM can be the ini-
tial subtype [20].
The criteria of ICHD-3β require presence of headache
on at least 15 days/month for at least 3 months, and es-
tablish a diagnostic treatment link to migraine day. It re-
quires migraine with/without an aura or relieved by a
triptan or ergot derivative on ≥ 8 days/month. However,
it might be too restrictive for application. Firstly, pa-
tients with CM often have difficulty recalling their prior
migraine attacks as required by item B. Secondly, when
analgesic agents are used, migraine features are often
not typical or characteristic. Moreover, even migraine-
Fig. 2 Treatment response of chronic migraine. ICHD-3β: International Classification of Headache Disorders,3rd edition beta version; EO: Expert
Opinion criteria
Table 4 Diagnostic criteria for CM according to S-L, ICHD-3β and EO criteria
S-L ICHD-3β EO
A. Daily or almost daily (>15 days a month)
head pain for >1 month
A. Headache on ≥15 days per month for at least
3 months
A. Headache on ≥15 days per month for at
least 3 months
B. Average headache duration of >4 h a day
(if untreated)
B. Occurring in a patient who has had at least 5
attacks fulfilling criteria for 1.1 Migraine without
aura and/or 1.2 migraine with aura
B. On ≥8 days per month on average
≥4 hours/day for at least 3 months, 1 or
more of the following criteria were fulfilled
1. Criteria C and D for 1.1 migraine without
aura
2. Criteria B and C for 1.2 migraine with aura
3. Criteria A and B for 1.5 probable migraine
C. At least one of the following:
1. History of episodic migraine meeting
any HIS criteria 1.1-1.6
2. History of increasing headache
frequency with deceasing severity of
migrainous features over at least 3
months
3. Headache at some time meets HIS
criteria for migraine 1.1-1.6 other than
duration
C. On ≥8 days per month for at least 3 months,
one or more of the following criteria were
fulfilled
1. Criteria C and D for 1.1 migraine without aura
2. Criteria B and C for 1.2 migraine with aura
3. Believed by the patient to be migraine at
onset and relieved by a triptan or ergot
derivative
C. Not better accounted for by another ICHD-3
diagnosis
D. Dose not meet criteria for new daily
persistent headache (4.7) or hemicrania
compounds continua (4.8)
D. Not better accounted for by another ICHD-3
diagnosis.
D. Does not meet criteria for new daily
persistent headache (4.7) or hemicrania
continua (4.8)
Abbreviations: S-L silberstein and lipton criteria, ICHD-3β international classification of headache disorders, 3rd edition beta version, EO expert opinion criteria, CM
chronic migraine
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specific analgesics can be effective against other primary
headaches, such as cluster headaches, as well as other
secondary headaches.
ICHD-3β requires migraine-specific medication as
one of the criteria, as patients in some countries took
triptans prescribed by their headache clinics, and this
could increase the sensitivity of the criteria [21]. A
survey in Italy showed that triptans were used by
46.4 % of patients with a previous diagnosis of mi-
graine [17]. Another survey in Latin American showed
that 70 % of MOH overused ergotamine, and most of
them were migraine sufferers prior to MOH [22].
However, in our population in China, very few patients
used triptans or ergot derivatives for treatment of mi-
graine episodes [5, 11, 23]. This may be because that
other types of analgesics were not only effective and
cheaper than tripans. In this study, just one patient
tried triptans, and triptans worked in this patient. The
patient had consulted to stop triptans out of overuse.
Although PM is considered a migraine subtype by the
ICHD-3β, PM days are not counted as migraine days
in the CM criteria. Thus some CrH with PM cannot
be classified and had no specific diagnosis.
Headache experts proposed revised criteria (EO) in
2014 [10]. The new criteria (1) removed the criterion B
that requires CM to occur in a patient with ≥ 5 prior mi-
graine episodes; (2) added PM to C3 regarding treatment
and relief of headache by a triptan or ergot agent, and
(3) added a requirement that the headache does not
meet criteria for NDPH or hemicrania continua. In our
study, 70 (26.8 %) patients had atypical migraine epi-
sodes, fulfilled the PM [9]. Analyze the 70 PM patients
according to the PM criteria, the most criteria not satis-
fied with was criterion D (associated symptoms), which
were up to 70 % (49/70); and criterion B (typical head-
ache duration) was not satisfied in 11.4 % (8/70); criter-
ion C (typical headache features) in 18.6 % (13/70).
Migraine attacks might resolve quickly if treated early in
the course and before the full symptom complex de-
velops. Additionally, a study in Turkish had reported
that migraine characteristics, especially associated symp-
toms, were less prominent in the CM population, and
the phenotype of CM may be associated with the course
of classification [24]. So, allowing probable migraines to
be a justification for the patient taking a “migraine day”,
also serves to include less developed attacks without
relying on a migraine-specific treatment response [25].
Among 261 CM patients fulfilling EO criteria, female
patients (191, 73.2 %) predominated. This was similar
to previous results [5, 26]. The average of age of our
patients was 49.5 years, consistent with earlier studies
[5, 27]. Most of our patients reported a relatively low
level of formal education, which was consistent with
our previous study [5]. These patients with CM had an
average duration of migraine attacks of 17.4 years, al-
though this is shorter than in another recent study
[28]. We note that 82.5 % of our patients took acute
analgesics, and 67.6 % had MOH, which was similar to
other studies [16, 29, 30]. Finally, the proportion of pa-
tients with a positive family headache history was simi-
lar to our previous study [5].
Our study was not designed to investigate therapeutic
strategies or agents for the treatment of CM, but it did
suggest that most patients with CM benefited from 3 to
6-months of treatment with medications for migraine
prophylaxis.
Conclusion
This study was designed to field-test the new EO criteria
for CM, beside the ICHD-3β criteria. Migraine-specific
analgesics are rarely used in China, accounting for 0.4 %
of the agents overused. Given that the ICHD-3β criteria
utilize treatment with migraine-specific medication as
one of the key data points, it makes this clinical tool less
applicable in our clinical setting, and argues for use of
the EO criteria. Our results indicate that CrH with PM
should be classified into CM based on EO, which will
allow more CM sufferers to receive correct diagnosis
and adequate treatment. The EO criteria appear to in-
crease the diagnostic sensitivity without lowering specifi-
city, and should be adopted in CM management practice
in our setting. Also in our setting, permitting patients
with PM to avail themselves of “migraine days” is a rea-
sonable accommodation for treatment of this difficult
condition.
Limitation
This was a retrospective study and selection bias was in-
evitable. In addition, we treated these patients using
medications for migraine prophylaxis. Therefore, further
study is needed to establish the efficacy and safety of
migraine-specific medications, including different agents,
dosage forms, and routes of administration. Moreover,
we did not evaluate the disability of these patients, and
the factor should be taken into consideration when
evaluating the impact of headache. And given that our
data were based on patients referred to a specialty clinic
for neurological disease, it necessarily will not represent
profiles of migraine sufferers in the general population.
Clinical implication
This study was of major importance for neurologists be-
cause chronic migraine (CM) is a disabling disorder that
is underdiagnosed and undertreated, and diagnostic cri-
teria for CM remain controversial. In addition, this study
analyzed the clinical profiles of CM and to field test the
ICHD-3β and Expert Opinion criteria for CM. Migraine-
specific analgesics are rarely used in China, permitting
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patients with probable migraine to avail themselves of
“migraine days” is a reasonable accommodation for this
difficult condition. The Expert Opinion criteria appear
to increase the diagnostic sensitivity without lowering
specificity, and should be adopted in CM management
practice in our setting.
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